Your browser doesn't support javascript.
loading
Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis.
Torgutalp, Murat; Rios Rodriguez, Valeria; Dilbaryan, Ani; Proft, Fabian; Protopopov, Mikhail; Verba, Maryna; Rademacher, Judith; Haibel, Hildrun; Sieper, Joachim; Rudwaleit, Martin; Poddubnyy, Denis.
Afiliação
  • Torgutalp M; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Rios Rodriguez V; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Dilbaryan A; Department of Internal Medicine, Moscow City Clinical Hospital, Moscow, Russia.
  • Proft F; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Protopopov M; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Verba M; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Rademacher J; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Haibel H; Berlin Institute of Health at Charite, Berlin, Germany.
  • Sieper J; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Rudwaleit M; Department of Gastroenterology, Infectious Diseases and Rheumatology (Including Nutrition Medicine), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Poddubnyy D; Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld University, Bielefeld, Nordrhein-Westfalen, Germany.
Ann Rheum Dis ; 2022 Jun 13.
Article em En | MEDLINE | ID: mdl-35697486
ABSTRACT

OBJECTIVE:

The objective of the current study was to analyse the association between treatment with tumour necrosis factor inhibitors (TNFi) and radiographic spinal progression in patients with axial spondyloarthritis (axSpA) from a long-term inception cohort.

METHODS:

A total of 243 patients with axSpA from the German Spondyloarthritis Inception Cohort with at least two sets of spinal radiographs obtained at least 2 years apart during a 10-year follow-up were included. Spinal radiographs were evaluated by three trained and calibrated readers according to the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). The association between the current TNFi, previous TNFi and radiographic spinal progression defined as the absolute mSASSS change score over 2 years was analysed using longitudinal generalised estimating equations analysis.

RESULTS:

TNFi treatment in the current 2-year interval was not associated with retardation of radiographic spinal progression (ß=-0.02 (95% CI -0.37 to 0.34) and -0.17 (95% CI -0.54 to 0.20) for any and ≥12 months treatment duration, respectively, adjusted for sex, the Ankylosing Spondylitis Disease Activity Score, smoking, presence of definite radiographic sacroiliitis, mSASSS at baseline and non-steroidal anti-inflammatory drug intake). TNFi treatment in the previous 2-year interval, was, however, significantly associated with reduction of mSASSS progression, which was especially evident in patients who received TNFi in the previous and in the current intervals ß=-0.58 (95% CI -1.02 to -0.13), adjusted for the same variables.

CONCLUSION:

TNFi treatment was associated with a time-shifted effect on radiographic spinal progression in axSpA that became evident between years 2 and 4 after treatment initiation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha